Glioblastoma multiforme (GBM) is the most common malignant, primary brain tumor with a median overall survival of only 15 months. The major challenges in treating GBM are the self-renewal capability of GBM cells and GBM stem cells (GSCs) which drive the development of treatment-resistant tumor variants; the heterogeneous composition, consisting of different cell types and of tumor cells at different stages of mutation; and the presence of the blood brain barrier (BBB), which acts as a protective boundary between the circulatory system and the brain parenchyma, hampering drug access to the central nervous systems (CNS). Therefore, treatment options for GBM are extremely limited, highlighting the need for newer and more efficient therapies able to address the above challenges.